Tofacitinib versus Biologic Treatments in Moderate-to-Severe Rheumatoid Arthritis Patients Who Have Had an Inadequate Response to Nonbiologic DMARDs: Systematic Literature Review and Network Meta-Analysis
Table 1
Results for monotherapy as obtained with random-effects network meta-analysis at 24 weeks: TOF 5 mg BID and TOF 10 mg BID versus treatment.
Treatment (monotherapy)
ACR20 OR (95% CI)
ACR50 OR (95% CI)
ACR70 OR (95% CI)
Withdrawals due to AEs OR (95% CI)
ACR20 OR (95% CI)
ACR50 OR (95% CI)
ACR70 OR (95% CI)
Withdrawals due to AEs OR (95% CI)
TOF 5 mg BID versus other treatments
TOF 10 mg BID versus other treatments
TOF 5 mg BID
NA
NA
NA
NA
1.75 (0.47, 6.68)
1.32 (0.33, 5.43)
1.72 (0.33, 10.17)
2.42 (0.30, 16.27)
TOF 10 mg BID
0.57 (0.15, 2.13)
0.76 (0.18, 3.02)
0.58 (0.10, 2.99)
0.41 (0.06, 3.35)
NA
NA
NA
NA
TCZ 8 mg/kg Q4W
0.54 (0.03, 10.36)
0.69 (0.04, 15.01)
0.24 (0.01, 13.81)
0.06 (0.00, 1.48)
0.95 (0.06, 17.60)
0.92 (0.05, 20.57)
0.42 (0.01, 24.62)
0.15 (0.01, 2.74)
CZP 400 mg Q4W
0.43 (0.04, 4.19)
0.63 (0.06, 8.63)
0.21 (0.00, 8.31)
0.13 (0.01, 3.89)
0.75 (0.07, 7.53)
0.84 (0.08, 11.60)
0.38 (0.00, 14.99)
0.33 (0.01, 7.29)
ETN 25 mg BIW
0.31 (0.03, 3.25)
0.38 (0.03, 5.17)
0.24 (0.00, 6.32)
0.61 (0.02, 20.95)
0.55 (0.05, 5.69)
0.51 (0.04, 6.69)
0.42 (0.01, 11.53)
1.47 (0.06, 41.85)
ADA 40 mg QW
0.76 (0.08, 7.30)
0.83 (0.08, 9.62)
0.32 (0.01, 7.84)
0.11 (0.01, 1.58)
1.34 (0.14, 13.42)
1.10 (0.11, 12.91)
0.57 (0.02, 14.64)
0.26 (0.02, 2.90)
ADA 40 mg Q2W
1.03 (0.11, 10.06)
1.60 (0.14, 18.27)
0.53 (0.02, 13.52)
0.05 (0.01, 0.51)
1.81 (0.19, 17.41)
2.10 (0.21, 23.35)
0.92 (0.04, 24.17)
0.13 (0.01, 0.93)
PLBO
3.70 (0.90, 13.16)
5.06 (1.25, 20.37)
4.36 (0.70, 24.15)
0.38 (0.06, 2.88)
6.47 (1.61, 23.13)
6.69 (1.73, 27.65)
7.60 (1.33, 44.03)
0.92 (0.15, 5.27)
Comparable; more effective. OR > 1 favors TOF 5 mg; OR < 1 favors TOF 5 mg; OR > 1 favors TOF 10 mg; OR < 1 favors TOF 10 mg.
